RayKnowChina Research Map
Shortlist

ChangshaCentral South University (Xiangya)

Xiangya Hospital

中南大学湘雅医院

Listed for 39 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xiangya Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌63 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  3. Hepatocellular carcinoma肝细胞癌119 papers led3 open trials led
  4. Stomach cancer胃癌35 papers led
  5. Hepatoblastoma肝母细胞瘤5 papers led
  6. Retinoblastoma视网膜母细胞瘤2 papers led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤15 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led1 open trial led
  10. Neuroblastoma神经母细胞瘤4 papers led
  11. Ewing sarcoma尤文肉瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤8 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  14. Aplastic anaemia再生障碍性贫血3 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  16. Beta thalassaemiaβ 地中海贫血1 paper led
  17. Haemophilia A血友病 A1 paper led
  18. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  19. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜2 papers led
  20. Fanconi anaemia范可尼贫血1 paper led
  21. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led
  22. IgG4-related diseaseIgG4相关性疾病1 paper led
  23. Myasthenia gravis重症肌无力20 papers led
  24. Moyamoya disease烟雾病6 papers led
  25. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  26. Takayasu arteritis大动脉炎1 paper led
  27. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  28. Amyotrophic lateral sclerosis肌萎缩侧索硬化症23 papers led
  29. Spinal muscular atrophy脊髓性肌萎缩症2 papers led
  30. Fabry disease法布雷病0 papers led
  31. Pompe disease庞贝病0 papers led
  32. Duchenne muscular dystrophy杜氏肌营养不良3 papers led
  33. Behçet disease白塞病1 paper led
  34. Alport syndromeAlport 综合征0 papers led
  35. IgA nephropathyIgA 肾病4 papers led
  36. Osteogenesis imperfecta成骨不全症1 paper led
  37. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  38. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  39. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 63 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 2.6%.

Papers led
63
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 131320212022: 141420222023: 8820232024: 111120242025: 15152025

5 hospitals in Changsha for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  2. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  3. Recruiting
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06788002

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

  4. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  5. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  6. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  7. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  8. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  9. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgeryPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led63
  1. A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.2026Cancer scienceFree full text
  2. A Novel Peculiarity of TXNIP Reversing the Radioresistance of NPC and Inducing Ferroptosis by xCT-GSH-GPX4-ROS Axis.2026Head & neck
  3. Vinburnine Sensitizes Radiotherapy Efficacy in Nasopharyngeal Carcinoma by Triggering Pyroptosis and Immune Responses via Activation of EDAR-NFκB Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function.2025Cell death & diseaseFree full text
  5. HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  6. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  7. Chemoradiotherapy Strategies for Immunotherapy-Sensitive Multi-Metastatic Nasopharyngeal Carcinoma: A Comparative Case Report and Literature Review.2025Current oncology (Toronto, Ont.)Free full text
  8. Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis.2025Head & neck
  9. USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance.2025International journal of biological sciencesFree full text
  10. Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.2025Journal of translational medicineFree full text
  11. ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance.2025Molecular cancer therapeutics
  12. HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17.2025Oncogene
  13. The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma.2025Scientific reportsFree full text
  15. Financial toxicity-related factors in patients with nasopharyngeal carfcinoma: a cross-sectional study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  16. Malnutrition Indicate Poor Clinical Outcome in Patients With NPC: A Multicenter Cohort Study.2025The Laryngoscope
  17. Classifications of Postradiation Nasopharyngeal Necrosis for Guiding Transnasal Endoscopic Nasopharyngeal Skull Base Surgery.2025The Laryngoscope
  18. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.2024Cell death & diseaseFree full text
  19. Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma.2024Cell death & diseaseFree full text
  20. HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  21. Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  22. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.2024Head & neck
  23. ANXA6 expression as a potential indicator of tumor diagnosis, metastasis and immunity in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  24. LncRNA BC200 promotes the development of EBV-associated nasopharyngeal carcinoma by competitively binding to miR-6834-5p to upregulate TYMS expression.2024International journal of biological macromolecules
  25. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  26. CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  27. Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma.2024Journal of medical virology
  28. Transcriptional pausing induced by ionizing radiation enables the acquisition of radioresistance in nasopharyngeal carcinoma.2024Journal of molecular cell biologyFree full text
  29. Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CE2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  30. HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma.2023Cancer letters
  31. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.2023Cell biology and toxicology
  32. Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  33. The effects of doxorubicin loaded aptamer S3-linked DNA tetrahedrons on nasopharyngeal carcinoma.2023Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeFree full text
  34. A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma.2023Journal of translational medicineFree full text
  35. Radiosensitization of Nasopharyngeal Carcinoma by Graphene Oxide Nanosheets to Reduce Bcl-2 Level.2023Langmuir : the ACS journal of surfaces and colloids
  36. Proteomics Profiling Reveals the Molecular Signatures and Potential Therapeutic Targets of Human Nasopharyngeal Carcinoma.2023Molecular & cellular proteomics : MCPFree full text
  37. CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma.2022Cell death & diseaseFree full text
  38. MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.2022Cell death & diseaseFree full text
  39. CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis.2022Cell death & diseaseFree full text
  40. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.2022Frontiers in immunologyFree full text
  41. Radiosensitizer EXO-miR-197-3p Inhibits Nasopharyngeal Carcinoma Progression and Radioresistance by Regulating the AKT/mTOR Axis and HSPA5-mediated Autophagy.2022International journal of biological sciencesFree full text
  42. TBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma.2022International journal of biological sciencesFree full text
  43. PGC1α-mediated fatty acid oxidation promotes TGFβ1-induced epithelial-mesenchymal transition and metastasis of nasopharyngeal carcinoma.2022Life sciences
  44. A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma.2022Molecular cancerFree full text
  45. Efficacy of chemoradiotherapy in survival of stage Ⅳ nasopharyngeal carcinoma and establishment of a prognostic model.2022Oral oncology
  46. Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  47. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  48. Neutrophil-to-lymphocyte ratio trend: A novel prognostic predictor in patients with nasopharyngeal carcinoma receiving radiotherapy.2022The International journal of biological markers
  49. Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.2022The Laryngoscope
  50. CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK.2022World journal of surgical oncologyFree full text
  51. Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma.2021AgingFree full text
  52. The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis.2021Annals of palliative medicine
  53. Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.2021Biochemical pharmacology
  54. EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinoma.2021Cell death & diseaseFree full text
  55. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma.2021Cell death & diseaseFree full text
  56. The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  57. Magnetic resonance imaging-based radiogenomics analysis for predicting prognosis and gene expression profile in advanced nasopharyngeal carcinoma.2021Head & neck
  58. Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.2021Head & neck
  59. The role of Exosomes in the Pathogenesis of Nasopharyngeal Carcinoma and the involved Clinical Application.2021International journal of biological sciencesFree full text
  60. Brain-Specific Relative Biological Effectiveness of Protons Based on Long-term Outcome of Patients With Nasopharyngeal Carcinoma.2021International journal of radiation oncology, biology, physics
  61. Galectin‑3 facilitates the proliferation and migration of nasopharyngeal carcinoma cells via activation of the ERK1/2 and Akt signaling pathways, and is positively correlated with the inflammatory state of nasopharyngeal carcinoma.2021Molecular medicine reportsFree full text
  62. CircRNA circTRAF3 promotes nasopharyngeal carcinoma metastasis through targeting miR-203a-3p/AKT3 axis.2021Pathology, research and practice
  63. Paradoxical effects of DNA tumor virus oncogenes on epithelium-derived tumor cell fate during tumor progression and chemotherapy response.2021Signal transduction and targeted therapyFree full text
Chinese-language papers (not in the count)3
  1. Causes of missed MRI diagnosis of radiotherapy-induced temporal lobe injury in nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. [Application of temporalis muscle flap in repair and reconstruction after the resection of tumor or necrotic foci following radiotherapy of nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  3. [Clinical study on endoscopic surgery for soft tissue necrosis of cranial base after radiotherapy for nasopharyngeal carcinoma].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status18
  1. Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomicsStatus unknownNCT05547971Lead sponsorStart 2022-09
  2. Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal CarcinomaCompletedNCT01449942Lead sponsorPhase 1/Phase 2Start 2009-05
  3. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07
  4. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  5. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  6. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Study sitePhase 2Start 2025-06
  7. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  8. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  9. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  10. LDRT and Chemoimmunotherapy in NPC With Liver MetastasisRecruitingNCT06788002Study sitePhase 2Start 2025-01
  11. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  12. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  13. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Study sitePhase 2Start 2022-10
  14. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Study siteStart 2022-11
  15. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  16. Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaCompletedNCT03984357Study sitePhase 2Start 2020-03
  17. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  18. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)49
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncologyarticle
  2. Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems2025Open Research (University of Surrey)article
  3. CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner2025Research Squarepreprint
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncologyconference-abstract
  5. Optimization of the 9th Ajcc/Uicc Tnm Staging System for Nasopharyngeal Carcinoma Based on Age and Pretreatment Ebv DNA: Exploring Prognostic Stratification and Individualized Treatment Strategies for Stage Ii-Iii Patients2025SSRN Electronic Journalpreprint
  6. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  7. 153P Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study2024Immuno-Oncology Technologyarticle
  8. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  9. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  10. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  11. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  12. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  13. Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.2024Journal of Clinical Oncologyconference-abstract
  14. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Squarepreprint
  15. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)preprint
  16. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  17. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023Venue not listedother
  18. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  19. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  20. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  21. Additional file 11 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  22. Additional file 12 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  23. Additional file 13 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  24. Additional file 14 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  25. Additional file 15 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  26. Additional file 16 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  27. Additional file 17 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  28. Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  29. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  30. Additional file 2 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  31. Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  32. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  33. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  34. Additional file 4 of Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop2022Figsharedataset
  35. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  36. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  37. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  38. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  39. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  40. Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma2022Process Biochemistryarticle
  41. Functional Characterization of p53 in NPC C666-1 Cells by CRISPR-Based Gene Knockout and Transcriptome Sequencing2022SSRN Electronic Journalpreprint
  42. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  43. Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  44. Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  45. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  46. Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy2021bioRxiv (Cold Spring Harbor Laboratory)preprint
  47. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  48. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  49. [Retracted] MicroRNA‑214 promotes proliferation and inhibits apoptosis via targeting Bax in nasopharyngeal carcinoma cells2021Molecular Medicine Reportsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 2220242025: 222025

3 hospitals in Changsha for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsSurgeryNeoadjuvant & combined treatment
Departments in papersMedical oncologyPathology / laboratory medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.2025International immunopharmacology
  2. MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.2025International journal of molecular medicineFree full text
  3. Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter?2024Bioscience reportsFree full text
  4. Classification and prediction of chemoradiotherapy response and survival from esophageal carcinoma histopathology images.2024Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  5. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.2022Advances in therapy
  6. OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma.2022Genetics researchFree full text
  7. Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.2021Journal of cellular physiology
  8. Silencing of UAP1L1 inhibits proliferation and induces apoptosis in esophageal squamous cell carcinoma.2021Molecular carcinogenesis
Chinese-language papers (not in the count)1
  1. [Clinical and prognostic features of the patients with esophageal squamous cell carcinomas as a first primary malignancy].2021Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
All its trials on ClinicalTrials.gov, any status1
  1. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
More papers found outside PubMed (not counted)7
  1. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncologyarticle
  2. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  3. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figsharedataset
  4. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  5. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  6. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset
  7. Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report2021Venue not listedpreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 119 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
119
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 262620212022: 353520222023: 232320232024: 151520242025: 19192025

6 hospitals in Changsha for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT06746701

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya Hospital; 1 listed hospital as study siteChangsha, Guangzhou

  2. Recruiting
    Antiviral Therapy for Patients With Liver Cancer After Surgery
    Phase
    Not given
    Started
    2021-12
    Registry
    NCT05466565

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya HospitalChangsha

  3. Enrolling by invitation
    JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT06882876

    Age 18 years to 75 years (registered criteria)

    Led by Xiangya HospitalChangsha

  4. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led119
  1. Quantitative Assessment of Peritumoral Stiffness Using Shell Elastography Enhances the Differentiation of Hepatocellular Carcinoma From Metastatic Liver Carcinoma.2026Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  2. Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Gamma-glutamyltransferase and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta‑analysis and systematic review.2025BMC gastroenterologyFree full text
  4. Primary liver cancer disease burden in Cambodia during 1990-2021: a systematic analysis of datasets from the global burden of disease study 2021.2025BMC gastroenterologyFree full text
  5. Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.2025BMJ openFree full text
  6. The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ.2025Cancer gene therapy
  7. CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop.2025Cell death & diseaseFree full text
  8. SLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.2025European journal of medical researchFree full text
  9. A Novel Signature Composed of Hypoxia, Glycolysis, Lactylation Related Genes to Predict Prognosis and Immunotherapy in Hepatocellular Carcinoma.2025Frontiers in bioscience (Landmark edition)
  10. Deubiquitylating Enzymes in Hepatocellular Carcinoma.2025International journal of biological sciencesFree full text
  11. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  12. LncRNA FTX accelerates the progression of hepatocellular carcinoma by FTX/miR-374a-3p/HMGB1 pathway.2025International journal of medical sciencesFree full text
  13. CDC5L binds to ELAVL1 to inhibit pyroptosis in hepatocellular carcinoma through the Caspase 3/GSDME signaling pathway.2025International journal of molecular medicineFree full text
  14. USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid.2025Journal for immunotherapy of cancerFree full text
  15. Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.2025Journal for immunotherapy of cancerFree full text
  16. MRI Tomoelastography to Assess the Combined Status of Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI
  17. The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  18. Comprehensive analysis reveals the prognostic and immunological role of PSMD13 in hepatocellular carcinoma.2025Mammalian genome : official journal of the International Mammalian Genome SocietyFree full text
  19. The molecular characteristics of DNA damage and repair related to P53 mutation for predicting the recurrence and immunotherapy response in hepatocellular carcinoma.2025Scientific reportsFree full text
  20. Long noncoding RNA semaphorin 6A-antisense RNA 1 reduces hepatocellular carcinoma by promoting semaphorin 6A mRNA degradation.2025World journal of gastroenterologyFree full text
  21. BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and Pyroptosis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  22. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.2024Biochimica et biophysica acta. Molecular basis of disease
  23. Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1.2024Cancer gene therapy
  24. A Novel Amino Acid-Related Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma.2024Cancer reports (Hoboken, N.J.)Free full text
  25. The survival prediction analysis and preliminary study of the biological function of YEATS2 in hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  26. ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A.2024Cellular signalling
  27. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.2024European journal of gastroenterology & hepatologyFree full text
  28. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.2024European journal of medicinal chemistry
  29. UCHL3 inhibits ferroptosis by stabilizing β-catenin and maintains stem-like properties of hepatocellular carcinoma cells.2024Free radical biology & medicine
  30. Comprehensive molecular classification predicted microenvironment profiles and therapy response for HCC.2024Hepatology (Baltimore, Md.)Free full text
  31. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.2024Hepatology international
  32. Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study.2024Journal for immunotherapy of cancerFree full text
  33. Deep learning based automatic internal gross target volume delineation from 4D-CT of hepatocellular carcinoma patients.2024Journal of applied clinical medical physicsFree full text
  34. The comprehensive roles of lncRNA FAM99A/FAM99B in hepatocellular carcinoma: Expressions, regulatory mechanisms and functional pathway analysis.2024Life sciences
  35. A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma.2024MedicineFree full text
  36. Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  37. Development of tryptophan metabolism patterns to predict prognosis and immunotherapeutic responses in hepatocellular carcinoma.2023AgingFree full text
  38. miR-195-5p Targets CDK1 To Regulate New DNA Synthesis and Inhibit the Proliferation of Hepatocellular Carcinoma Cells.2023Applied biochemistry and biotechnology
  39. Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.2023BMC cancerFree full text
  40. Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.2023Biochemical pharmacology
  41. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.2023Biology directFree full text
  42. Acyl-CoA thioesterase 12 suppresses YAP-mediated hepatocarcinogenesis by limiting glycerolipid biosynthesis.2023Cancer letters
  43. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.2023Cancer medicineFree full text
  44. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.2023Cancer medicineFree full text
  45. Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study.2023Cancer medicineFree full text
  46. Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.2023Cancer scienceFree full text
  47. The deubiquitinase EIF3H promotes hepatocellular carcinoma progression by stabilizing OGT and inhibiting ferroptosis.2023Cell communication and signaling : CCSFree full text
  48. Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.2023Cell communication and signaling : CCSFree full text
  49. Sorcin regulate pyroptosis by interacting with NLRP3 inflammasomes to facilitate the progression of hepatocellular carcinoma.2023Cell death & diseaseFree full text
  50. USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization.2023Cell death & diseaseFree full text
  51. RNF2 inhibits E-Cadherin transcription to promote hepatocellular carcinoma metastasis via inducing histone mono-ubiquitination.2023Cell death & diseaseFree full text
  52. A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  53. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.2023Computers in biology and medicine
  54. WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  55. Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.2023EpigeneticsFree full text
  56. The Hepatic Nerves Regulated Inflammatory Effect in the Process of Liver Injury: Is Nerve the Key Treating Target for Liver Inflammation?2023Inflammation
  57. Evaluation of the efficacy and safety of CalliSpheres® microsphere-transarterial chemoembolization in large hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  58. DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.2023Life sciences
  59. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy.2022ACS nano
  60. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma.2022AgingFree full text
  61. The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.2022AgingFree full text
  62. The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.2022AgingFree full text
  63. Clinical utility of serum fucosylated fraction of alpha-fetoprotein in the diagnostic of hepatocellular carcinoma: a comprehensive analysis with large sample size.2022AgingFree full text
  64. A comprehensive analysis of FOX family in HCC and experimental evidence to support the oncogenic role of FOXH1.2022AgingFree full text
  65. Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.2022AgingFree full text
  66. An M0 macrophage-related prognostic model for hepatocellular carcinoma.2022BMC cancerFree full text
  67. Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.2022BioMed research internationalFree full text
  68. LncRNA FIRRE promotes the proliferation and metastasis of hepatocellular carcinoma by regulating the expression of PXN through interacting with MBNL3.2022Biochemical and biophysical research communications
  69. The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma.2022Cancer research
  70. Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway.2022Cell transplantationFree full text
  71. Exosomal microRNA-25 released from cancer cells targets SIK1 to promote hepatocellular carcinoma tumorigenesis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  72. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.2022Digestive diseases and sciencesFree full text
  73. G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.2022Disease markersFree full text
  74. Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.2022Disease markersFree full text
  75. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.2022Disease markersFree full text
  76. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.2022Frontiers in immunologyFree full text
  77. Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker.2022Frontiers in immunologyFree full text
  78. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  79. Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  80. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.2022International journal of biological sciencesFree full text
  81. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.2022International journal of biological sciencesFree full text
  82. Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling.2022International journal of biological sciencesFree full text
  83. Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  84. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.2022Journal of translational medicineFree full text
  85. Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.2022Liver international : official journal of the International Association for the Study of the Liver
  86. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.2022Oncogene
  87. The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma.2022PeerJFree full text
  88. Analysis of mutations in DNA damage repair pathway gene in Chinese patients with hepatocellular carcinoma.2022Scientific reportsFree full text
  89. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.2022Scientific reportsFree full text
  90. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection.2022Scientific reportsFree full text
  91. Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI.2022Scientific reportsFree full text
  92. Role of CD68 in tumor immunity and prognosis prediction in pan-cancer.2022Scientific reportsFree full text
  93. Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma.2022World journal of surgical oncologyFree full text
  94. YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.2021AgingFree full text
  95. Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma.2021AgingFree full text
  96. Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression.2021BMC bioinformaticsFree full text
  97. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.2021BMC cancerFree full text
  98. Loss of androgen receptor promotes HCC invasion and metastasis via activating circ-LNPEP/miR-532-3p/RAB9A signal under hypoxia.2021Biochemical and biophysical research communications
  99. Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.2021Cancer biotherapy & radiopharmaceuticals
  100. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma.2021Cancer letters
  101. NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1α signaling in hepatocellular carcinoma.2021Cancer scienceFree full text
  102. GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway.2021CarcinogenesisFree full text
  103. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.2021Cell death & diseaseFree full text
  104. BTB/POZ domain-containing protein 7/hypoxia-inducible factor 1 alpha signalling axis modulates hepatocellular carcinoma metastasis.2021Clinical and translational medicineFree full text
  105. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.2021Clinical science (London, England : 1979)
  106. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients2021Clinics and research in hepatology and gastroenterology
  107. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  108. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.2021Frontiers in immunologyFree full text
  109. Integrative Transcriptomic, Proteomic and Functional Analysis Reveals ATP1B3 as a Diagnostic and Potential Therapeutic Target in Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  110. A new survival model based on ion channel genes for prognostic prediction in hepatocellular carcinoma.2021Genomics
  111. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.2021International journal of biological sciencesFree full text
  112. The strategy and efficacy of prophylaxis against hepatitis B virus recurrence after liver transplantation for HBV-related diseases in the era of potent nucleos(t)ide analogues: A meta-analysis.2021Journal of digestive diseases
  113. Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer.2021Journal of food biochemistry
  114. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractFree full text
  115. Hepatic macrophages: Key players in the development and progression of liver fibrosis.2021Liver international : official journal of the International Association for the Study of the Liver
  116. Microvascular invasion, an important clinical feature that should be deeply explored in hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  117. ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/β-Catenin Signaling.2021Molecular cancer research : MCRFree full text
  118. Deregulated 14-3-3ζ and methionine adenosyltransferase α1 interplay promotes liver cancer tumorigenesis in mice and humans.2021OncogeneFree full text
  119. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.2021Pathology oncology research : PORFree full text
Chinese-language papers (not in the count)1
  1. [Research progress of serum biomarkers for early screening of hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status15
  1. JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib StudyEnrolling by invitationNCT06882876Lead sponsorPhase 1Start 2025-07
  2. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.RecruitingNCT06746701Lead sponsorStart 2023-05
  3. Antiviral Therapy for Patients With Liver Cancer After SurgeryRecruitingNCT05466565Lead sponsorStart 2021-12
  4. An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCCCompletedNCT05932836Lead sponsorStart 2023-03
  5. Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent HepatocarcinomaStatus unknownNCT05240404Lead sponsorPhase 2Start 2020-07
  6. Thermal Ablation Followed by Immunotherapy for HCCStatus unknownNCT03864211Lead sponsorPhase 1/Phase 2Start 2019-06
  7. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  8. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT05313282Study sitePhase 3Start 2022-06
  9. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Study sitePhase 2Start 2022-03
  10. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  11. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma PatientsStatus unknownNCT05343832Study siteStart 2021-11
  12. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  13. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  14. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT02956772Study sitePhase 2Start 2016-11
  15. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 35 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
35
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 121220232024: 4420242025: 332025

4 hospitals in Changsha for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  2. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImaging & AI
Departments in papersMedical oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led35
  1. Enhancing gastric ultrasound training with standardized patient-based drinking simulation: a self-controlled study.2025BMC medical educationFree full text
  2. High-fidelity optical platform for multiplex glutathione profiling links redox dynamics to tumor progression and auxiliary diagnosis.2025Biosensors & bioelectronics
  3. Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.2025Communications biologyFree full text
  4. PMEPA1 promotes gastric cancer cell proliferation by regulating the ubiquitin-mediated degradation of 14-3-3σ and promoting cell cycle progression.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  5. Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.2024Irish journal of medical science
  6. Facilitating endoscopic full-thickness resection for gastric submucosal tumors with a novel snare traction method (with video).2024Journal of gastroenterology and hepatology
  7. A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer.2024Scientific reportsFree full text
  8. Single-cell profiling reveals tumour cell heterogeneity accompanying a pre-malignant and immunosuppressive microenvironment in gastric adenocarcinoma.2023Clinical and translational medicineFree full text
  9. Classification of precancerous lesions based on fusion of multiple hierarchical features.2023Computer methods and programs in biomedicine
  10. Gastric Cancer with Sarcopenia: an Area Worth Focusing On.2023Current treatment options in oncology
  11. Simultaneous incision and suturing of a large wound in the full-layer resection of stromal tumor under the traction of a snare -- a new method of endoscopic suturing.2023EndoscopyFree full text
  12. Traction and resection in treating gastric submucosal tumor growing extraluminally by using two snares like a ropeway.2023EndoscopyFree full text
  13. Early gastric mucosa-associated lymphoid tissue lymphoma treated by endoscopic submucosal dissection.2023EndoscopyFree full text
  14. Systematic evaluation of the safety and therapeutic effects of para-aortic lymphadenectomy for advanced gastric cancer: a systematic review and meta-analysis.2023European review for medical and pharmacological sciences
  15. FLOT1 promotes gastric cancer progression and metastasis through BCAR1/ERK signaling.2023International journal of biological sciencesFree full text
  16. Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing.2023Molecular oncologyFree full text
  17. Incidence trends and survival analysis of appendiceal tumors in the United States: Primarily changes in appendiceal neuroendocrine tumors.2023PloS oneFree full text
  18. Comprehensive analysis regarding the prognostic significance of downregulated ferroptosis-related gene AKR1C2 in gastric cancer and its underlying roles in immune response.2023PloS oneFree full text
  19. Comparison of endoscopic full-thickness resection and ligation-assisted endoscopic full-thickness resection for small (≤ 1.5 cm) gastric subepithelial tumors originating from muscularis propria.2023Surgical endoscopy
  20. The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer.2022AgingFree full text
  21. miR-511-5p Suppresses Cell Migration, Invasion and Epithelial-Mesenchymal Transition Through Targeting PAK2 in Gastric Cancer.2022Biochemical genetics
  22. Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer.2022Clinical and translational medicineFree full text
  23. E2F5 promotes proliferation and invasion of gastric cancer through directly upregulating UBE2T transcription.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  24. Extracellular Vesicles Promote the Formation of Pre-Metastasis Niche in Gastric Cancer.2022Frontiers in immunologyFree full text
  25. Study on the Expression of β-1,3-N-acetylglucosaminyltransferase 3 in Gastric Cancer and the Mechanism Promoting Gastric Cancer Progression Based on the Extraction Method of Nanomagnetic Beads.2022Journal of biomedical nanotechnology
  26. Establishment and Validation for Predicting the Lymph Node Metastasis in Early Gastric Adenocarcinoma.2022Journal of healthcare engineeringFree full text
  27. Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer.2022Journal of immunology researchFree full text
  28. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.2022Molecular and cellular biochemistry
  29. Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy.2021AgingFree full text
  30. EBV as a high infection risk factor promotes RASSF10 methylation and induces cell proliferation in EBV-associated gastric cancer.2021Biochemical and biophysical research communications
  31. Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.2021Endoscopy
  32. Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.2021Immunopharmacology and immunotoxicology
  33. Progress of Gastric Cancer Surgery in the era of Precision Medicine.2021International journal of biological sciencesFree full text
  34. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.2021Journal of immunology researchFree full text
  35. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.2021OncogeneFree full text
Chinese-language papers (not in the count)2
  1. Predictive value of preoperative L3-SMI, AGR, and PNI for overall survival in patients undergoing radical gastrectomy for gastric cancer.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Gender differences in systemic inflammatory and nutritional index following radical surgery for advanced gastric cancer.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status19
  1. The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric CancerActive, not recruitingNCT07080879Lead sponsorN/AStart 2023-06
  2. Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric CancerStatus unknownNCT04005365Lead (inferred)Phase 2Start 2019-11
  3. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  4. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  5. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  10. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  11. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  12. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  13. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  14. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  15. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  16. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  17. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  18. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  19. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 5 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 3.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 112025

3 hospitals in Changsha for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Changsha for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. The prognostic significance of different degrees of resection of skull base chordoma.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Earlier papers (2016–2020)2
  1. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.2017Neurosurgery
  2. [Pretemporal transcavernous approach tailored surgery of cavernous sinus tumors: a consecutive series of 31 cases report].2016Zhonghua wai ke za zhi [Chinese journal of surgery]

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 2220232024: 3320242025: 552025

14 hospitals in Changsha for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery
Papers it led15
  1. PLEKHF1 Induces Mitochondrial Dysfunction to Inhibit Osteosarcoma Growth and Metastasis.2025IUBMB life
  2. Demethylase, ALKBH1, regulates osteosarcoma chemosensitivity through FZD8/Wnt/β-catenin signaling pathway in the m7G manner.2025International journal of biological macromolecules
  3. Eriodictyol-cisplatin coated nanomedicine synergistically promote osteosarcoma cells ferroptosis and chemosensitivity.2025Journal of nanobiotechnology
  4. CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification.2025Molecular medicine (Cambridge, Mass.)
  5. Identification and validation of SAC3D1 as a prognostic biomarker promoting the development of osteosarcoma.2025Scientific reports
  6. Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways.2024Journal of biomedical science
  7. Osteosarcoma neutrophil extracellular trap network-associated gene recurrence and metastasis model.2024Journal of cancer research and clinical oncology
  8. The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.2024Scientific reports
  9. Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma.2023Scientific reports
  10. Use of LARS for soft tissue function reconstruction during tumor-type hemi-shoulder replacement achieves a good prognosis: a retrospective cohort study.2023World journal of surgical oncology
  11. METTL3 upregulates COPS5 expression in osteosarcoma in an m6A-related manner to promote osteosarcoma progression.2022Experimental cell research
  12. Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients.2022Scientific reports
  13. Ferroptosis-related gene signature associates with immunity and predicts prognosis accurately in patients with osteosarcoma.2021Cancer science
  14. circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.2021Cancer science
  15. A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.2021Frontiers in immunology
Chinese-language papers (not in the count)1
  1. Clinical application of LARS tumor tube in joint function reconstruction of tumor type artificial hip replacement.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Earlier papers (2016–2020)17
  1. Functionalized BaTiO3 enhances piezoelectric effect towards cell response of bone scaffold.2020Colloids and surfaces. B, Biointerfaces
  2. miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion.2020International journal of molecular medicine
  3. Letter to the Editor on the article "Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis" (Int J Surg 2019; Nov 15;72:206-213. doi: 10.1016/j.ijsu.2019.11.004. [Epub ahead 2020International journal of surgery (London, England)
  4. miR-139-mediated NOTCH1 regulation is crucial for the inhibition of osteosarcoma progression caused by resveratrol.2020Life sciences
  5. Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis.2020Signal transduction and targeted therapy
  6. Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.2020Theranostics
  7. The possible role of insulin-like growth factor-1 in osteosarcoma.2019Current problems in cancer
  8. MicroRNA-340-5p suppresses osteosarcoma development by down-regulating the Wnt/β-catenin signaling pathway via targeting the STAT3 gene.2019European review for medical and pharmacological sciences
  9. Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics.2019The American journal of the medical sciences
  10. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.2018Cancer science
  11. Distraction-suppression effect on osteosarcoma.2018Medical hypotheses
  12. Is double-approach surgery and tenodesis without a gastrocnemius flap better for dealing with proximal fibular osteosarcoma?2018World journal of surgical oncology
  13. Nd-induced honeycomb structure of intermetallic phase enhances the corrosion resistance of Mg alloys for bone implants.2017Journal of materials science. Materials in medicine
  14. MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  15. Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-κB/IL-6 signals.2016European journal of pharmacology
  16. JNK pathway in osteosarcoma: pathogenesis and therapeutics.2016Journal of receptor and signal transduction research
  17. MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A.2016Oncotarget

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

3 hospitals in Changsha for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
    Phase
    N/A
    Started
    2023-02
    Registry
    NCT05751733

    Age 18 years to Not stated (registered criteria)

    Led by Xiangya HospitalChangsha

  2. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led4
  1. The feasibility of endoscopic resection for esophageal gastrointestinal stromal tumor.2025Surgical endoscopy
  2. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.2024Cell communication and signaling : CCS
  3. CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor.2023Scientific reports
  4. Endoscopic management of the rare situation where a gastric stromal tumor specimen falls into the nasopharynx.2021Endoscopy
Earlier papers (2016–2020)6
  1. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.2020World journal of surgical oncology
  2. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis.2019Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. [Correlation of CT imaging features and CT texture analysis parameters with pathologic risk stratification 
in gastric stromal tumors].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Option for different surgeries in treating small gastrointestinal stromal tumors].2018Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  5. Four synchronous primary cancers of the aerodigestive tract and thyroid.2017Asian cardiovascular & thoracic annals
  6. Concomitant stromal tumor and early cancer of the stomach: What should be done?2017Medicine
All its trials on ClinicalTrials.gov, any status3
  1. Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GISTRecruitingNCT05751733Lead sponsorN/AStart 2023-02
  2. Entacapone Combination With Imatinib for Treatment of GISTCompletedNCT04006769Lead sponsorEarly phase 1Start 2020-10
  3. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

8 hospitals in Changsha for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryNeurology
Papers it led4
  1. HNRNPA2B1 and HNRNPR stabilize ASCL1 in an m6A-dependent manner to promote neuroblastoma progression.2024Biochimica et biophysica acta. Molecular basis of disease
  2. Exosomal circBBS2 inhibits ferroptosis by targeting miR-494 to activate SLC7A11 signaling in ischemic stroke.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic 2022Frontiers in endocrinology
  4. Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.2022Molecular neurobiology
Earlier papers (2016–2020)5
  1. PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.2018Journal of molecular cell biology
  2. Exogenous Hydrogen Sulfide Protects SH-SY5Y Cells from OGD/RInduced Injury.2017Current molecular medicine
  3. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.2017Oncotarget
  4. [Effect of neuroglobin on oxygen-glucose deprivation and reoxygenation induced autophagy in a human neuroblastoma cell line].2017Zhonghua yi xue za zhi
  5. Genome-wide analysis of DNA methylation during antagonism of DMOG to MnCl2-induced cytotoxicity in the mouse substantia nigra.2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 2220242025: 112025

4 hospitals in Changsha for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsStem cell transplantKidney & bone complications
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led8
  1. Construction of a machine learning-based screening model for IgD myeloma.2025Clinica chimica acta; international journal of clinical chemistry
  2. Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1.2024Cancer chemotherapy and pharmacology
  3. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.2024Cancer medicineFree full text
  4. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.2022Oncogene
  6. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.2022The Journal of clinical investigationFree full text
  7. An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients.2021AgingFree full text
  8. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.2021The Journal of clinical investigationFree full text
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  2. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  3. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11
  4. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  5. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenPhiladelphia chromosome & geneticsAntibody & targeted drugs
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 3 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.7%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Changsha for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimens
Papers it led1
  1. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.2024Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)1
  1. [Febrile infection-related epilepsy syndrome caused by hemophagocytic lymphohistiocytosis: a case report].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Changsha for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia.2022Nature medicine
Chinese-language papers (not in the count)1
  1. [Rare thalassemia caused by novel nucleotide variants in the globin gene: four case reports and literature review].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruitingNCT05577312Study sitePhase 1/Phase 2Start 2022-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

  3. Recruiting
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT07644832

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study.2022Hematology (Amsterdam, Netherlands)
Earlier papers (2016–2020)2
  1. A study of the stressors and coping behaviors of parents of Chinese hemophilic children.2017Journal of child health care : for professionals working with children in the hospital and community
  2. In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs.2016Scientific reports
All its trials on ClinicalTrials.gov, any status21
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  3. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  4. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Study sitePhase 3Start 2024-11
  5. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  6. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  7. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  8. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  9. Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without InhibitorCompletedNCT05619926Study sitePhase 2Start 2023-01
  10. A Phase I of SS109 in Hemophilia A or and B With InhibitorsCompletedNCT05651061Study sitePhase 1Start 2022-12
  11. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  12. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  13. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  14. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  15. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  16. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  17. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04060836Study sitePhase 1Start 2019-05
  18. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  19. Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia AStatus unknownNCT02888223Study sitePhase 1Start 2016-09
  20. Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia AStatus unknownNCT02921945Study sitePhase 3Start 2016-10
  21. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Chinese-language papers (not in the count)1
  1. [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 2 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 3.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Changsha for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

2 hospitals in Changsha for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  2. Recruiting
    A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06697535

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAcute attack treatmentAntibodies & diagnosisRelapse prevention
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 1 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Changsha for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesHead, eye socket & salivary glands
Departments in papersENT / head & neck surgerySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology
Papers it led1
  1. Gastrointestinal: A case of IgG4-related disease involving intestinal tract and orbital cavity.2023Journal of gastroenterology and hepatology
Chinese-language papers (not in the count)1
  1. [Analysis of diagnosis and treatment of IgG4-related disease involving the nasal cavity and skull base(with 8 case reports)].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 20 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 4.0%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 3320232024: 7720242025: 332025

4 hospitals in Changsha for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07622342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

  4. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  5. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  6. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisStandard immunotherapyThymus & thymectomy
Departments in papersNeurologyPediatricsMedical oncology
Papers it led20
  1. Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.2025Journal of neurology
  2. Comparison of Efficacy Between Lymphoplasmapheresis and Plasma Exchange in Myasthenic Crisis.2025Muscle & nerve
  3. Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study.2024European journal of neurologyFree full text
  5. Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.2024Human genomicsFree full text
  6. Immune repertoire profiling in myasthenia gravis.2024Immunology and cell biology
  7. Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.2024Orphanet journal of rare diseasesFree full text
  10. Pediatric Ocular Myasthenia Gravis: Single-Center Experience.2024Pediatric neurology
  11. Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate.2023Annals of medicineFree full text
  12. Evidence for genetic causal relationships between gut microbiome, metabolites, and myasthenia gravis: a bidirectional Mendelian randomization study.2023Frontiers in immunologyFree full text
  13. The value of postoperative radiotherapy in thymoma patients with myasthenia gravis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  14. Risk factors associated with adverse pregnancy outcomes and postpartum exacerbation in women with myasthenia gravis.2022American journal of reproductive immunology (New York, N.Y. : 1989)
  15. Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center.2022Frontiers in immunologyFree full text
  16. Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications.2022Journal of autoimmunity
  17. Characteristics of myasthenia gravis in elderly patients: a retrospective study.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  18. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.2021Frontiers in immunologyFree full text
  19. Evaluation of outcome measures for myasthenia gravis subgroups.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  20. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.2021Journal of immunology researchFree full text
All its trials on ClinicalTrials.gov, any status12
  1. A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisRecruitingNCT07622342Study sitePhase 2Start 2026-08
  2. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  5. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  7. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  8. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09
  9. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisStatus unknownNCT05716035Study sitePhase 2/Phase 3Start 2023-04
  10. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  11. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12
  12. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 6 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.7%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 0020242025: 112025

1 hospital in Changsha for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersNeurosurgeryNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

3 hospitals in Changsha for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPediatrics
Papers it led2
  1. Clinical and radiological features, treatment responses and prognosis in pediatric patients with co-existing anti-N-methyl-D-aspartate receptor and myelin oligodendrocyte glycoprotein antibody-associated encephalitis: A single center study.2024Multiple sclerosis and related disorders
  2. Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 9 children with refractory N-methyl-D-aspartate receptor antibody encephalitis children treated with tocilizumab].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)5
  1. A survey on pediatric anti-N-methyl-D-aspartate-receptor encephalitis treatment strategies in China.2020Chinese medical journal
  2. [Cryptococcal Encephalitis Complicating Anti-N-methyl-D-aspartate Receptor Encephalitis in an Immunosuppressed Patient].2020Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Clinical features of anti-N-methyl-D-aspartate receptor encephalitis and the concomitant seizure].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  4. [Clinical analysis of 71 cases of anti-N-methyl-D-aspartate receptor encephalitis in children].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.2017Journal of neuroimmunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Changsha for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

7 hospitals in Changsha for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Papers it led4
  1. Clinical characteristics and all-cause mortality in female patients with idiopathic pulmonary fibrosis in Chinese population.2025Journal of global health
  2. Smoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis.2024Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  3. Psoriasis may increase the risk of idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2024Respiratory research
  4. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.2024Scientific reports
Earlier papers (2016–2020)4
  1. Molecular pathogenesis involved in human idiopathic pulmonary fibrosis based on an integrated microRNA‑mRNA interaction network.2018Molecular medicine reports
  2. [Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography].2017Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis.2016Biochemical and biophysical research communications
  4. miR‑221 targets HMGA2 to inhibit bleomycin‑induced pulmonary fibrosis by regulating TGF‑β1/Smad3-induced EMT.2016International journal of molecular medicine
All its trials on ClinicalTrials.gov, any status4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  3. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  4. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Study sitePhase 3Start 2012-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 23 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 2.9%.

Papers led
23
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 5520222023: 4420232024: 2220242025: 552025

4 hospitals in Changsha for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led23
  1. Brain metabolic imaging with 18 F-PET-CT and machine-learning clustering analysis reveal divergent metabolic phenotypes in patients with amyotrophic lateral sclerosis.2026European journal of nuclear medicine and molecular imaging
  2. Exploring the Causal Association Between 91 Circulating Inflammatory Proteins and Neurodegenerative Diseases: A Bidirectional Two-Sample Mendelian Randomization and Bioinformatics Analysis.2025Brain and behavior
  3. Shape Alterations of Subcortical Nuclei Correlate With Amyotrophic Lateral Sclerosis Progression.2025Brain and behavior
  4. Association of Reduced Brain Metabolism With Motor Function and Survival in Amyotrophic Lateral Sclerosis Patients With Neurofilament Heavy (NEFH) Gene Mutation.2025European journal of neurology
  5. Retinal alterations induced by amyotrophic lateral sclerosis: An analysis using optical coherence tomography.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  6. Medulla oblongata dominated synaptic density network degeneration in amyotrophic lateral sclerosis.2025NeuroImage. Clinical
  7. Mutation and clinical analysis of the CLCC1 gene in amyotrophic lateral sclerosis patients from Central South China.2024Annals of clinical and translational neurology
  8. Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.2024Frontiers of medicine
  9. Neutralizing peripheral circulating IL1β slows the progression of ALS in a lentivirus-infected OPTNE478G mouse model.2023Animal models and experimental medicine
  10. Biomarkers in cerebrospinal fluid for amyotrophic lateral sclerosis phenotypes.2023Annals of clinical and translational neurology
  11. Brain metabolic signatures in patients with genetic and nongenetic amyotrophic lateral sclerosis.2023CNS neuroscience & therapeutics
  12. ALS-plus related clinical and genetic study from China.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  13. Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  14. CYLD variants identified in Alzheimer's disease and frontotemporal dementia patients.2022Annals of clinical and translational neurology
  15. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using 18 F-SynVesT-1 positron emission tomography.2022European journal of neurology
  16. Mitochondrial genome variations are associated with amyotrophic lateral sclerosis in patients from mainland China.2022Journal of neurology
  17. Association of variants in the KIF1A gene with amyotrophic lateral sclerosis.2022Translational neurodegeneration
  18. Genetics of frontotemporal dementia in China.2021Amyotrophic lateral sclerosis & frontotemporal degeneration
  19. A Step-by-Step Refined Strategy for Highly Efficient Generation of Neural Progenitors and Motor Neurons from Human Pluripotent Stem Cells.2021Cells
  20. Downregulation of TOP2 modulates neurodegeneration caused by GGGGCC expanded repeats.2021Human molecular genetics
  21. Spreading of pathological TDP-43 along corticospinal tract axons induces ALS-like phenotypes in Atg5+/- mice.2021International journal of biological sciences
  22. Mutation spectrum of amyotrophic lateral sclerosis in Central South China.2021Neurobiology of aging
  23. Rare, pathogenic variants in LRP10 are associated with amyotrophic lateral sclerosis in patients from mainland China.2021Neurobiology of aging
Chinese-language papers (not in the count)1
  1. [Heterogeneity in the regulation of cellular stress responses by FUS gene mutations associated with amyotrophic lateral sclerosis].2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Earlier papers (2016–2020)16
  1. Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis.2020Current neurovascular research
  2. Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China.2020Neurobiology of aging
  3. Eye tracking metrics to screen and assess cognitive impairment in patients with neurological disorders.2020Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients.2020Scientific reports
  5. Advances in genetics research in the pathogenesis of amyotrophic lateral sclerosis.2020Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  6. [Proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique].2019Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness.2018Current neurovascular research
  8. ALS-Associated E478G Mutation in Human OPTN (Optineurin) Promotes Inflammation and Induces Neuronal Cell Death.2018Frontiers in immunology
  9. Identification of CHCHD2 mutations in patients with Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia in China.2018Molecular medicine reports
  10. Mutation analysis of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis and frontotemporal dementia.2018Neurobiology of aging
  11. [Mutations of G38R and D40G cause amyotrophic lateral sclerosis by reducing Annexin A11 protein stability].2018Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  12. Mutations of CCNF gene is rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia from Mainland China.2017Amyotrophic lateral sclerosis & frontotemporal degeneration
  13. Identification of CHCHD10 Mutation in Chinese Patients with Alzheimer Disease.2017Molecular neurobiology
  14. High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China.2016Brain : a journal of neurology
  15. Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China.2016Clinical genetics
  16. Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 2 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Changsha for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurology
Papers it led2
  1. Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.2025BMC pediatrics
  2. Postural Tremor Caused by Hirayama Disease Mimicking Essential Tremor.2024Tremor and other hyperkinetic movements (New York, N.Y.)
All its trials on ClinicalTrials.gov, any status4
  1. A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular AtrophyActive, not recruitingNCT07617779Study siteN/AStart 2024-04
  2. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01
  3. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11
  4. Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyCompletedNCT04089566Study sitePhase 3Start 2020-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseStatus unknownNCT06114329Study sitePhase 2Start 2023-10
  2. A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedNCT04974749Study sitePhase 3Start 2022-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy DrugActive, not recruitingNCT05793307Study sitePhase 1/Phase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 3 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 1.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

5 hospitals in Changsha for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Changsha for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 112025

7 hospitals in Changsha for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07390123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led4
  1. Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy.2025BMC nephrology
  2. Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy.2023Immunologic research
  3. C5a enhances Vδ1 T cells recruitment via the CCL2-CCR2 axis in IgA nephropathy.2023International immunopharmacology
  4. A Partial Picture of the Single-Cell Transcriptomics of Human IgA Nephropathy.2021Frontiers in immunology
Earlier papers (2016–2020)11
  1. Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study.2020BMC nephrology
  2. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.2020Clinical and experimental nephrology
  3. Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy.2020Journal of nephrology
  4. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.2020Medical science monitor : international medical journal of experimental and clinical research
  5. Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.2019Frontiers in cellular and infection microbiology
  6. Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis.2018International urology and nephrology
  7. NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.2018Journal of translational medicine
  8. Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.2018Molecular and cellular biochemistry
  9. Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.2018Renal failure
  10. Losartan and Dexamethasone may inhibit chemotaxis to reduce the infiltration of Th22 cells in IgA nephropathy.2017International immunopharmacology
  11. Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.2016The Indian journal of medical research
All its trials on ClinicalTrials.gov, any status3
  1. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Changsha for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

2 hospitals in Changsha for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Chinese-language papers (not in the count)1
  1. [Research progress of intestinal-hepatic axis in primary biliary cholangitis].2025Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Changsha for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. ANXA1 is identified as a key gene associated with high risk and T cell infiltration in primary sclerosing cholangitis.2023Human genomics
All its trials on ClinicalTrials.gov, any status1
  1. CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)Active, not recruitingNCT05896137Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Changsha for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Extensive metabolic disorders are present in APC(min) tumorigenesis mice.2016Molecular and cellular endocrinology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中南大学湘雅医院

Xiangya Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Xiangya Hospital of Central South University; Xiangya Hospital Central South University; XiangYa Hospital; Xiangya Hospital of Central South University (H. Yang); Clinical Anatomy Center of Xiangya Hospital; Xiangya Hospital of Centre-south University; General Surgery of Xiangya Hospital

Suggest a correctionDownload the data